James Allison - Jounce Therapeutics Co-Founder

JNCEDelisted Stock  USD 1.88  0.00  0.00%   

Founder

Dr. James P. Allison, Ph.D. is a cofounder of Jounce Therapeutics and currently serves as chair of The University of Texas MD Anderson Cancer Center Department of Immunology and director of the Immunotherapy Platform. A leading tumor immunologist, Dr. Allison has a longstanding interest in mechanisms of Tcell development and activation, the development of novel strategies for tumor immunotherapy and is recognized as the first person to isolate the Tcell antigen receptor protein. His research led to the clinical development of ipilimumab, which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Previously, he was director of the Ludwig Center for Cancer Immunotherapy and the chair of the immunology program at the Memorial SloanKettering Cancer Center, as well as the David H. Koch Chair in Immunologic Studies and attending immunologist at Memorial SloanKettering Cancer Center. Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine, and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Previously, he served as president of the American Association of Immunologists. He has received numerous awards, including the Centeon Award for Innovative Breakthroughs in Immunology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, the AAIDana Award in Human Immunology Research and the C. Chester Stock Award for Distinguished Achievement in Biomedical Research. Dr. Allison recently received an AACRSU2CCRI cancer immunotherapy dream team grant, for which he will serve as the Dream Team leader
Professional MarksPh.D
Phone857 259 3840
Webhttps://jouncetx.com
Allison received his B.S. in microbiology and his Ph.D. in biological sciences from the University of Texas.

James Allison Latest Insider Activity

Tracking and analyzing the buying and selling activities of James Allison against Jounce Therapeutics stock is an integral part of due diligence when investing in Jounce Therapeutics. James Allison insider activity provides valuable insight into whether Jounce Therapeutics is net buyers or sellers over its current business cycle. Note, Jounce Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Jounce Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Jounce Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.1404) % which means that it has lost $0.1404 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2503) %, meaning that it created substantial loss on money invested by shareholders. Jounce Therapeutics' management efficiency ratios could be used to measure how well Jounce Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Jounce Therapeutics currently holds 11.89 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Jounce Therapeutics has a current ratio of 6.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Jounce Therapeutics' use of debt, we should always consider it together with its cash and equity.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 137 people. Jounce Therapeutics (JNCE) is traded on NASDAQ Exchange in USA and employs 141 people.

Management Performance

Jounce Therapeutics Leadership Team

Elected by the shareholders, the Jounce Therapeutics' board of directors comprises two types of representatives: Jounce Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jounce. The board's role is to monitor Jounce Therapeutics' management team and ensure that shareholders' interests are well served. Jounce Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jounce Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Richard Murray, President CEO, Director
CPA CPA, CFO Treasurer
Drew MD, Founder
Hugh Cole, Chief Business Officer and Head of Corporate Development
Robert Schreiber, Founder
Padmanee MD, Founder
Louis MD, Founder
James Allison, Co-Founder
Elizabeth MD, Chief Officer

Jounce Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jounce Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Consideration for investing in Jounce Stock

If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk